Updated:
Wacker Chemie
Alexander Wacker founded the business in 1914 in Burghausen, Bavaria, originally producing acetaldehyde and acetone.
Wacker Chemie
Alexander Wacker founded the business in 1914 in Burghausen, Bavaria, originally producing acetaldehyde and acetone. Over more than a century it evolved into a publicly traded, family-influenced industrial group with four divisions — silicones, polymers, polysilicon and biosolutions — that together generated €6.4 billion in revenue in 2024 (per the firm, March 2025). The founding family retains control through a dual-class share structure, with the Wacker family holding voting rights well above their economic stake, which shapes a long-cycle investment posture uncommon among publicly listed peers. Capital allocation flows predominantly through organic capacity expansion at a handful of globally scaled production sites. The polysilicon business, anchored at a massive plant in Charleston, Tennessee and a sprawling integrated facility in Burghausen, serves the world's largest solar-wafer manufacturers. Speculative and cyclical by nature, polysilicon capex decisions run in multi-billion-euro tranches tied to decade-long electricity-supply agreements. The silicones and polymers divisions — producing dispersible polymer powders for construction and silicone elastomers for medical applications — deploy capital into downstream formulations capacity, with an explicit tilt toward specialty grades that carry higher margins than bulk commodity silicones. Bioengineered cyclodextrins and fermentation-derived cystine from the biosolutions unit represent a smaller, high-margin deployment vector. Wacker employs roughly 16,000 people across production sites in Germany, the United States, China and the Netherlands. The family's holding company, Dr. Alexander Wacker Familiengesellschaft mbH, consolidates the founding family's voting rights and sits clearly above the listed entity in the governance structure. In March 2025 the firm guided 2025 capital expenditures to roughly €950 million, concentrated on expanding semiconductor-grade polysilicon purification capacity in Burghausen — a direct response to reshoring trends in advanced chip manufacturing (per Reuters, March 2025). The germane structural differentiator is not simply product depth but the governance feedback loop between public-capital discipline and family-control patience. Unlike pure-play commodity-chemical firms, Wacker can absorb polysilicon price troughs that would trigger activist campaigns elsewhere, because the Wacker family's voting control insulates management from short-term earnings pressure. That architecture allowed the firm to hold its Charleston poly line through the 2012–2013 solar trade-war margin collapse, a posture that became rewarded when the Chinese polysilicon market restructured and prices normalized. The dual shareholder base — public equity for liquidity, family voting for horizon — is rare among German DAX-listed industrials of similar heft.
General information
Firm type
Asset Manager
Year founded
1914
AUM
Undisclosed
Location
Region
Europe
Country
Germany
City
Munich
Corporate office
Munich, Germany
Principals
Christian Hartel
President & CEO
Sector focus
Frequently asked questions
Who runs investment decisions at Wacker Chemie?
Capital allocation is driven by the four-member executive board led by President and CEO Christian Hartel, under the supervision of a supervisory board where the founding Wacker family holds significant representation through its controlling entity, Dr. Alexander Wacker Familiengesellschaft mbH. The dual-class share structure gives the family effective control over long-cycle capex decisions, with major polysilicon expansion programs typically requiring both board consensus and ongoing dialogue with the family holding company.
How does the Wacker family maintain control of the company?
Through a dual-class share structure that grants the Dr. Alexander Wacker Familiengesellschaft mbH voting rights well in excess of its economic ownership of the listed entity. This governance architecture insulates the executive board from short-term activist pressure and has historically permitted countercyclical capacity investments — notably in polysilicon during the 2012–2013 solar trade-war downturn — that a widely held commodity-chemicals firm would struggle to justify to a typical shareholder base.
What is Wacker Chemie's exposure to the solar energy supply chain?
Polysilicon is the largest segment by asset intensity, with hyperpure polysilicon production sites in Burghausen, Germany and Charleston, Tennessee supplying solar-wafer manufacturers globally. The firm has disclosed that it supplies roughly half the solar-grade polysilicon market outside of China (per the firm's official communications, 2023). Revenues and margins in this division are structurally cyclical, tied to Chinese solar installation policy, global electricity prices, and wafer-inventory cycles.
Does the biosolutions division represent a material allocation of capital?
Biosolutions is the smallest of the four operating divisions by revenue and capex but carries the highest margin profile. Deployment targets cyclodextrin and cysteine biotech capacity — fermentation-derived specialty products — rather than commoditized industrial biotech. Capital commitments tend to be sub-€100 million increments and are funded from group cash flow rather than discrete project-finance structures.
How is semiconductor-grade polysilicon different from solar-grade for Wacker's investment posture?
Semiconductor-grade polysilicon requires dramatically higher purity thresholds and commands a multiple on per-kilogram pricing relative to solar-grade. Wacker's March 2025 capex guidance explicitly weights purification capacity for semiconductor applications, reflecting the post-Chips Act onshoring demand signal. The investment logic shares the same base chemistry as solar polysilicon but serves a structurally different buyer set — global foundries — and carries less correlation to solar installation cycles.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: